EPISODE · Mar 17, 2011 · 11 MIN
Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients
from Journal of Clinical Oncology (JCO) Podcast
By Reed Drews. This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al.
NOW PLAYING
Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients
0:00
11:06
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 11 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on March 17, 2011.
What is this episode about?
By Reed Drews. This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!